BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data

NEW YORK, March 21 | Thu Mar 21, 2013 8:06am EDT

NEW YORK, March 21 (Reuters) - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Back to top

Reuters.com

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.